Chronic kidney disease and its complications:
Erythropoetin stimulating agent can be divide into two phases:
- Correction: treatment commenced with the aim of achieving target Hb. It is reasonable in this phase to monitor Hb 2-4 weekly and iron stores monthly. The aim is a rise of Hb at a rate of approximately 10 g/l/month. Rapid correction of anaemia has been associated with hypertension and seizures
- Maintenance: target Hb is not fully defined in chronic kidney disease, but the range is between 100-115 g/L. There is evidence of potential harm when Hb is targeted to exceed 130 g/l. Monitoring of Hb and iron is generally at three monthly intervals during this phase.